Kynurenine upregulate immune checkpoint expression and promote TEX in CRC via upregulating TOX expression, while IDO1 inhibitors and TOX knockdown can restore the anti-tumor activity of CD8+ T cells (138). This evidence concerns the gene CD8A and neoplasm.